Genetic variants in Toll-Like Receptor 2 (TLR2), TLR4, TLR9, and FCγ receptor II are associated with antibody response to quadrivalent meningococcal conjugate vaccine in HIV-infected youth

Clinical and Vaccine Immunology

Volumn 20, Issue 6, 2013, Pages 848-857

  Spector, Stephen A ^a,b   Qin, Min ^c   Lujan Zilbermann, Jorge ^d   Singh, Kumud K ^a,b   Warshaw, Meredith G ^c   Williams, Paige L ^c   Jean Philippe, Patrick ^e   Fenton, Terence ^c   Siberry, George K ^f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b RADY CHILDREN'S HOSPITAL   (United States)

^c CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR IIA; INTERLEUKIN 10; MANNOSE BINDING LECTIN 2; MENINGOCOCCUS VACCINE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; BACTERIUM ANTIBODY; FC RECEPTOR; TLR2 PROTEIN, HUMAN; TLR4 PROTEIN, HUMAN; TLR9 PROTEIN, HUMAN; VACCINE;

ADOLESCENT; ADULT; ALLELE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CHILD; CONTROLLED STUDY; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE RESPONSE; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; MENINGOCOCCOSIS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SCHOOL CHILD; VIRUS LOAD; BLOOD; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MENINGITIS, MENINGOCOCCAL; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; CHILD; FEMALE; HIV INFECTIONS; HUMANS; MALE; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; POLYMORPHISM, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, IGG; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTOR 9; VACCINES, CONJUGATE; YOUNG ADULT;

EID: 84891437908     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00042-13     Document Type: Article

References (29)

1. Faber J, Henninger N, Finn A, Zenz W, Zepp F, Knuf M. 2009. A toll-like receptor 4 variant is associated with fatal outcome in children with invasive meningococcal disease. Acta Paediatr. 98:548-552.
2. Centers for Disease Control and Prevention. 2011. Recommendation of the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MenACWY-D) among children aged 9 through 23 months at increased risk for invasive meningococcal disease. MMWR Morb. Mortal. Wkly. Rep. 60:1391-1392.
3. Centers for Disease Control and Prevention. 2011. Licensure of a meningococcal conjugate vaccine for children aged 2 through 10 years and updated booster dose guidance for adolescents and other persons at increased risk for meningococcal disease. MMWR Morb. Mortal. Wkly. Rep. 60:1018-1019.
4. Siberry GK, Williams PL, Lujan-Zilbermann J, Warshaw MG, Spector SA, Decker MD, Heckman BE, Demske EF, Read JS, Jean-Philippe P, Kabat W, Nachman S, IMPAACT P1065 Protocol Team. 2010. Phase I/II, open-label trial of safety and immunogenicity of meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescents. Pediatr. Infect. Dis. J. 29:391-396.
5. Lujan-Zilbermann J, Warshaw MG, Williams PL, Spector SA, Decker MD, Abzug MJ, Heckman B, Manzella A, Kabat B, Jean-Philippe P, Nachman S, Siberry SK, IMPAACT P1065 Protocol Team. 2012. Immunogenicity and safety of 1 vs 2 doses of quadrivalent meningococcal conjugate vaccine in youth infected with human immunodeficiency virus. J. Pediatr. 161:676-681.
6. Davila S, Wright VJ, Khor CC, Sim KS, Binder A, Breunis WB, Inwald D, Nadel S, Betts H, Carrol ED, de Groot R, Hermans PW, Hazelzet J, Emonts M, Lim CC, Kuijpers TW, Martinon-Torres F, Salas A, Zenz W, Levin M, Hibberd ML, International Meningococcal Genetics Consortium. 2010. Genome-wide association study identifies variants in the CFH region associated with host susceptibility to meningococcal disease. Nat. Genet. 42:772-776.
7. Brouwer MC, de Gans J, Heckenberg SG, Zwinderman AH, van der Poll T, van de Beek D. 2009. Host genetic susceptibility to pneumococcal and meningococcal disease: a systematic review and meta-analysis. Lancet Infect. Dis. 9:31-44.
8. Wright V, Hibberd M, Levin M. 2009. Genetic polymorphisms in host response to meningococcal infection: the role of susceptibility and severity genes. Vaccine 27(Suppl 2):B90-B102.
9. Schmitt C, Villwock A, Kurzai O. 2009. Recognition of meningococcal molecular patterns by innate immune receptors. Int. J. Med. Microbiol. 299:9-20.
10. Moresco EM, LaVine D, Beutler B. 2011. Toll-like receptors. Curr. Biol. 21:R488-R493.
11. Beutler BA. 2009. TLRs and innate immunity. Blood 113:1399-1407.
12. Schmitt FA, Bigley JW, McKinnis R, Logue PE, Evans RW, Drucker JL. 1988. Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex. N. Engl. J. Med. 319:1573-1578. (Pubitemid 19003423)
13. Sjolinder H, Mogensen TH, Kilian M, Jonsson AB, Paludan SR. 2008. Important role for Toll-like receptor 9 in host defense against meningococcal sepsis. Infect. Immun. 76:5421-5428.
14. Brouwer MC, Read RC, van de Beek D. 2010. Host genetics and outcome in meningococcal disease: a systematic review and meta-analysis. Lancet Infect. Dis. 10:262-274.
15. Keyserling H, Papa T, Koranyi K, Ryall R, Bassily E, Bybel MJ, Sullivan K, Gilmet G, Reinhardt A. 2005. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch. Pediatr. Adolesc. Med. 159:907-913. (Pubitemid 41423328)
16. Borrow R, Andrews N, Goldblatt D, Miller E. 2001. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect. Immun. 69:1568-1573. (Pubitemid 32187610)
17. Jodar L, Cartwright K, Feavers IM. 2000. Standardisation and validation of serological assays for the evaluation of immune responses to Neisseria meningitidis serogroup A and C vaccines. Biologicals 28:193-197.
18. Moore CE, Hennig BJ, Perrett KP, Hoe JC, Lee SJ, Fletcher H, Brocklebank D, O'Connor D, Snape MD, Hall AJ, Segal S, Hill AV, Pollard AJ. 2012. Single nucleotide polymorphisms in the Toll-like receptor 3 and CD44 genes are associated with persistence of vaccine-induced immunity to the serogroup C meningococcal conjugate vaccine. Clin. Vaccine Immunol. 19:295-303.
19. Fransen F, Stenger RM, Poelen MC, van Dijken HH, Kuipers B, Boog CJ, van Putten JP, van Els CA, van der Ley P. 2010. Differential effect of TLR2 and TLR4 on the immune response after immunization with a vaccine against Neisseria meningitidis or Bordetella pertussis. PLoS One 5:e15692. doi:10.1371/journal. pone.0015692.
20. van Duin D, Medzhitov R, Shaw AC. 2006. Triggering TLR signaling in vaccination. Trends Immunol. 27:49-55. (Pubitemid 43083564)
21. Iwasaki A, Medzhitov R. 2004. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 5:987-995. (Pubitemid 41057715)
22. Gavin AL, Hoebe K, Duong B, Ota T, Martin C, Beutler B, Nemazee D. 2006. Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling. Science 314:1936-1938. (Pubitemid 46026117)
23. Schmidlin H, Diehl SA, Blom B. 2009. New insights into the regulation of human B-cell differentiation. Trends Immunol. 30:277-285.
24. Huggins J, Pellegrin T, Felgar RE, Wei C, Brown M, Zheng B, Milner EC, Bernstein SH, Sanz I, Zand MS. 2007. CpG DNA activation and plasma-cell differentiation of CD27-naive human B cells. Blood 109:1611-1619. (Pubitemid 46239595)
25. Capolunghi F, Cascioli S, Giorda E, Rosado MM, Plebani A, Auriti C, Seganti G, Zuntini R, Ferrari S, Cagliuso M, Quinti I, Carsetti R. 2008. CpG drives human transitional B cells to terminal differentiation and production of natural antibodies. J. Immunol. 180:800-808.
26. Bernasconi NL, Traggiai E, Lanzavecchia A. 2002. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 298:2199-2202. (Pubitemid 35471246)
27. Espeli M, Niederer HA, Traherne JA, Trowsdale J, Smith KG. 2010. Genetic variation, Fcγ receptors, KIRs and infection: the evolution of autoimmunity. Curr. Opin. Immunol. 22:715-722.
28. Findlow H, Southern J, Mabey L, Balmer P, Heyderman RS, Auckland C, Morris R, Miller E, Borrow R. 2006. Immunoglobulin G subclass response to a meningococcal quadrivalent polysaccharide-diphtheria toxoid conjugate vaccine. Clin. Vaccine Immunol. 13:507-510. (Pubitemid 44044838)
29. Platonov AE, Shipulin GA, Vershinina IV, Dankert J, van de Winkel JG, Kuijper EJ. 1998. Association of human FcγRIIa (CD32) polymorphism with susceptibility to and severity of meningococcal disease. Clin. Infect. Dis. 27:746-750. (Pubitemid 29244328)